~nifold %meritical star,enOs in the ~edia kindled the discussion on the treatment of primary breast cancer thus causing more confusion than olavifioation. At times those discussions suggest that oonssrvatire breast cancer therepy is a standard trentm~nt. ~us the I~21-sponsored multicentsr study "treatment of ~mall breast cancer" could be regarded as outdated. Ethically and scientifically this view must be vigoro~ly rejected. Aport from a large number of colleagues not having shy experience in breast preservation treatment, a broad renge of questions is still open. Preliminary restllts of other studies might suggest that conservative and radical therapy provide equal survival rates, but scientific proof is still lac ~king. Although the quaicy of radiation therapy has improved substantially conclusions still cermet be dra~n as to side-effects like demsge of nedghbeurd~ng organs, secondary tumors, etc. In our study, special emphasis will be given to pro~ostic factors which m~y exclude cert ~s~-n timbre fram conservetire therapy frc~ the outset. Another open question is the quality of life based on the a~lied treatment medality. The strict lo~t~ent selection criteria of our protocol guarautse progress on these questions. E%o ye~ra after activation of the ~T-Study, patient recruitment is still underway, so that results would be premature. As of October 19~5, 56 hos;itals had entered ~20 patients into the trial. At present the follo~dng positive aspects can be s~rmrized: -~u increased conscientiousness in operative te~d'miques as well as the histolcathological work-up of the specimens removed. -~ significant improvement in radiotherapy stendards. qhese are the absolutely necessary conditione for perfbmdng conservative breast cancer treslment without brd/~ing discredit on this therepeutic modality -s consideretiun that per se justifies our study's continuation, apart from the scientific obstanles outlined above. This multicenter tzi&1 is s~onsored by the ~unde~nistsriu~ fdr Forschtmg und Technologie (= ~67T).
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CPh 02 CLINICAL RELEVANCE OF IN VITRO CHEMOSENSITIVITY TESTING IN ACUTE LEUKEMIAS: FC Prischl, JD Schwarzmeier
The ready availability and convenient isolation procedures of leukemic blast cells makes human leukemia a favourable tarw for in vitro drug testing. For clinical use long term tests are insufficient as therapy has to be initiated within one or two days. -We have analyzed leukemic blasts for in vitro responsiveness to cytostatic agents in terms of suppression of labeled nucleoside precursor incorporation into cellular nucleic acids in a short term test with results available within 24 hours. Cell-line experiments showed that the percentage inhibition of precursor incorporation in independent from the proliferative activity of the cells. In previous retrospective studies the test system proved to be clinically applicable (Cancer 53:390,1984) . Thus, criteria prospectively indicating sensitivity or resistance of the blasts were evaluated. Using these new criteria cells from 46 leukemia patients (15 ALL, 21AML, G AMMk,I AUL, 3 CML-DC) were tested in a prospective "single blind" study. Our data show that 89% of the patients with in vitro sensitivity to one or more of the drugs used for therapy responded with complete or partial remission, A treatment failure correlated in 70% with in vitro resistance. Inthis small number of patients we also observed a trend that the probability to respond to therapy increased with the number of in vitro active drugs. -No correlation was found between in vitro results and the number of blast cells in peripheral blood or bone marrow. We also could not predict the duration of remission. However, it is interesting to note, that some individual patients with extremly high in vitro sensitivity (very high inhibition of precursor uptake) seemed to relapse earlier.
Ist Medical Clinic, University of Vienna, Lazarettg. 14, A-1090 Vienna, Austria. for drug testing in subsequent animal passages. In order to investigate if a tumor responds in nude mice in a similar way than in the patient 80 comparisons were performed in 55 tumors. Comparisons were done in carcinomas of the large bowel (27), lung (13), stomach (9), melanomas (8) and breast (4) and 19 in other tumors. Combination chemotherapy was more successful than single agent therapy. 21 tumors got a remission in the patient which was obtained in 19 cases in the nude mouse system, too. In 59 cases the treatment was unsuccessful in the patient and the same result was found in 57 cases in the nude mouse system. Xenografts gave a correct prediction for resistance in 96% and for tumor response in 90%. Despite great efforts to obtain a large number of comparisons only 32 test results were available before the patients needed treatment. Therefore, the xenograft system will not have practical significance in determining the treatment of the patients.
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BNA-flETABOLISN IN HUHAN BONE NARRDM CELLS: THYNIBINE-KINASE-ACTIVITY AS A ItARKER OF LEUKEIIIC BLAST POPULATIONS AND NUCLEOSIDE-INCORPORATION-ACTIVITY FOR PRE-DICTION DF PROGNOSIS
Limitations are the durations of the testing, the growth rate of only 50% and the charges for nude mice. However, the highly correct prediction rates for tumor sensitivity and resistance validates human tumor xenografts as tumor models to test new drugs and combinations. Furthermore, we use xenografts as tumor material for experiments in cell culture. 
